Patrick J. Lillie
Impact in
- Infectious Diseases top 0.05%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Health top 0.2%
- Vaccine Coverage and Hesitancy
Papers in
-
- SARS-CoV-2 and COVID-19 Research 26
- COVID-19 Clinical Research Studies 13
- SARS-CoV-2 detection and testing 5
- Epidemiology 28
- Influenza Virus Research Studies 8
- Sepsis Diagnosis and Treatment 7
- Respiratory viral infections research 6
- Co-authors
- Sarah C. Gilbert (7 shared papers)Tamara Katherine Berthoud (4 shared papers)Teresa Lambe (3 shared papers)Gavin D Barlow (19 shared papers)Matthew M. Hamill (3 shared papers)Rohit Bazaz (3 shared papers)A. L. N. Chapman (2 shared papers)Simon Dixon (1 shared paper)
- Journals
- The Lancet (13 papers)Journal of Infection (12 papers)The Lancet Respiratory Medicine (6 papers)The Lancet Infectious Diseases (4 papers)PLoS ONE (3 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Patrick J. Lillie
91 papers receiving 12.7k citations
Patrick J. Lillie's Hit Papers
Peers
Comparison fields: 5 of 164
- Infectious Diseases 8.2k
- Health 1.4k
- Modeling and Simulation 850
- Applied Microbiology and Biotechnology 162
- Neurology 1.2k
Countries citing papers authored by Patrick J. Lillie
This map shows the geographic impact of Patrick J. Lillie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick J. Lillie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick J. Lillie more than expected).
Fields of papers citing papers by Patrick J. Lillie
This network shows the impact of papers produced by Patrick J. Lillie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick J. Lillie. The network helps show where Patrick J. Lillie may publish in the future.
Co-authors
The 25 scholars most cited alongside Patrick J. Lillie, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 98 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Hit paper breakdown → | 2020 | 3621 |
| 2 | Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Hit paper breakdown → | 2021 | 867 |
| 3 | Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection Hit paper breakdown → | 2021 | 865 |
| 4 | SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses Hit paper breakdown → | 2022 | 740 |
| 5 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 641 |
| 6 | Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial Hit paper breakdown → | 2021 | 465 |
| 7 | SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway Hit paper breakdown → | 2022 | 457 |
| 8 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 9 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 10 | 2010 | 343 | |
| 11 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 12 | 2017 | 261 | |
| 13 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 14 | 2012 | 225 | |
| 15 | 2009 | 214 | |
| 16 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 17 | 2021 | 182 | |
| 18 | 2012 | 177 | |
| 19 | 2021 | 174 | |
| 20 | 2021 | 161 |
About Patrick J. Lillie
Patrick J. Lillie is a scholar working on Infectious Diseases, Epidemiology, Modeling and Simulation, Public Health, Environmental and Occupational Health and Applied Microbiology and Biotechnology, having authored 98 papers that have together received 13.0k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (26 papers), COVID-19 Clinical Research Studies (13 papers), Influenza Virus Research Studies (8 papers), Sepsis Diagnosis and Treatment (7 papers), Respiratory viral infections research (6 papers), COVID-19 epidemiological studies (5 papers), SARS-CoV-2 detection and testing (5 papers) and Long-Term Effects of COVID-19 (4 papers). The work is most often cited by research in Infectious Diseases (8.2k citations), Health (1.4k citations), Modeling and Simulation (850 citations), Applied Microbiology and Biotechnology (162 citations) and Neurology (1.2k citations). Patrick J. Lillie has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Sarah C. Gilbert, Tamara Katherine Berthoud, Teresa Lambe, Gavin D Barlow, Matthew M. Hamill, Rohit Bazaz, A. L. N. Chapman, Simon Dixon, Ahalya K. Malachira and Nathan James Brendish. Their work appears in journals such as The Lancet, Journal of Infection, The Lancet Respiratory Medicine, The Lancet Infectious Diseases and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.